Comparison of Lutein Bioaccessibility from Dietary Supplement-Excipient Nanoemulsions and Nanoemulsion-Based Delivery Systems

Lutein combined with EGCG improved retinitis pigmentosa against N-methyl-N nitrosourea-induced

In order to investigate the synergistic improving effect of lutein (LUT) and epigallocatechin-3-gallate (EGCG) treatment on retinitis pigmentosa (RP), an N-methyl-N-nitrosourea (MNU)-induced mouse model was conducted in the present study. Compared to the LUT alone treatment group, in the LUT combined with EGCG (LUT-EGCG) treatment group, the accumulation content of LUT was significantly increased by 50.24% in the liver. The morphological results indicated that LUT-EGCG treatment significantly improved the retina structure with the thickness of the outer nuclear layer restored to 185.28 ± 0.29 μm, showing no significant difference compared to the control group. The LUT-EGCG treatment also increased the production of short-chain fatty acids, such as acetic and propionic acids. Compared with the LUT alone treatment, the LUT-EGCG treatment significantly increased the relative abundance of Lachnospiraceae and Helicobacteraceae. RT-qPCR results indicated that LUT-EGCG treatment significantly increased the antiapoptotic gene Bcl-2 expression. In addition, the expression of IL-6 was significantly down-regulated in the LUT-EGCG group, while there was no significance in NF-κβ, TNF-α, IL-1β, and IL-18 compared with the LUT group. Correlation analysis supported the conclusion that LUT combined with EGCG may improve RP by modulating antiapoptotic gene expression and regulating the abundance of gut microbiota. However, the underlying mechanism still needs further research.

Lutein-Rich Beverage Alleviates Visual Fatigue in the Hyperglycemia Model of Sprague-Dawley Rats

Asthenopia is a syndrome based on the symptoms of eye discomfort that has become a chronic disease that interferes with and harms people's physical and mental health. Lutein is an internationally recognized "eye nutrient", and studies have shown that it can protect the retina and relieve visual fatigue. In this study, lutein was extracted from marigold (Tagetes erecta L.) and saponified. The purified lutein concentration measured by HPLC was 50.12 mg/100 g. Then, purified lutein was modified to be water-soluble by nanoscale modification and microencapsulation technology. Water-soluble lutein was then mixed with a leaching solution of Chinese wolfberry and chrysanthemum to make a functional beverage. The effects of this beverage on hepatic antioxidant enzymes and the alleviation of visual fatigue in a rat model of diabetes were investigated for 4 weeks. Lutein intake of 0.72 (medium-lutein beverage group) and 1.44 mg/mL (high-lutein beverage group) relieved visual fatigue, ameliorated turbidity symptoms of impaired crystalline lenses, reduced hepatic MDA concentration, increased hepatic GSH concentration, and significantly increased the activities of the hepatic antioxidant enzymes SOD, CAT, GSH-Px, and GR in rats. These data suggest that a lutein-rich beverage is an effective and harmless way to increase the total anti-oxidation capacity of lenses and alleviate visual fatigue.

Lutein–stachyose (LS) amphiphilic oligosaccharide derivatives improve the oral bioavailability of lutein

A new amphiphilic oligosaccharide derivative, based on lutein modification onto the OH position of stachyose with facile and mild esterification, was prepared and used to improve the oral bioavailability of lutein. The structures of lutein-stachyose derivative (LS) were confirmed by Fourier transform infrared spectroscopy and hydrogen-1 nuclear magnetic resonance, indicating that one stachyose is connected to one lutein through succinic acid. The critical micelle concentration of LS was approximately 6.86 ± 0.24 mg/mL, corresponding to the free lutein concentration of approximately 2.96 mg/mL. LS has better digestive stability and free radical scavenging ability, and it could inhibit the degradation of lutein in the gastrointestinal tract. Importantly, LS is nontoxic to cells and zebrafish embryos. In terms of oral bioavailability in rats, the AUC_0-12h values of LS were 2.26 times higher than those of free lutein. Therefore, stachyose modification is a promising strategy for improving the oral bioavailability of fat-soluble lutein.

Modified porous starches loading curcumin and improving the free radical scavenging ability and release properties of curcumin

Maize porous starch-curcumin microspheres were prepared by encapsulating curcumin into cross-linked porous starch and oxidized porous starch to investigate the effect of modified porous starch in embedding and protecting curcumin. The morphology and physicochemical properties of microspheres were analyzed using scanning electron microscopy, Fourier transform infrared spectroscopy (FT-IR), X-ray diffraction, Zeta/DLS, Thermal stability, and antioxidant activity; the release of curcumin was evaluated with a simulated gastric-intestine model. The FT-IR results revealed that curcumin was amorphously encapsulated in the composite and hydrogen bond formation between starch and curcumin was one of the major driving forces for encapsulation. Microspheres increased the initial decomposition temperature of curcumin, which has a protective effect on curcumin. Modification improved the encapsulation efficiency and the scavenging free radical ability of porous starch. The release mechanism of curcumin from microspheres fits first-order and Higuchi models well in gastric and intestinal models, respectively, indicating that encapsulation of curcumin within different porous starches microspheres enables controlled release of curcumin. To recapitulate, two different modified porous starch microspheres improved the drug loading, slow release and free radical scavenging effects of curcumin. Among them, the cross-linked porous starch microspheres had higher encapsulation and slow release ability for curcumin than the oxidized porous starch microspheres. It provides theoretical significance and data basis for the encapsulation of active substances by modified porous starch.

Carotenoids and Their Health Benefits as Derived via Their Interactions with Gut Microbiota

Carotenoids have been related to a number of health benefits. Their dietary intake and circulating levels have been associated with a reduced incidence of obesity, diabetes, certain types of cancer, and even lower total mortality. Their potential interaction with the gut microbiota (GM) has been generally overlooked but may be of relevance, as carotenoids largely bypass absorption in the small intestine and are passed on to the colon, where they appear to be in part degraded into unknown metabolites. These may include apo-carotenoids that may have biological effects because of higher aqueous solubility and higher electrophilicity that could better target transcription factors, i.e., NF-κB, PPARγ, and RAR/RXRs. If absorbed in the colon, they could have both local and systemic effects. Certain microbes that may be supplemented were also reported to produce carotenoids in the colon. Although some bactericidal aspects of carotenoids have been shown in vitro, a few studies have also demonstrated a prebiotic-like effect, resulting in bacterial shifts with health-associated properties. Also, stimulation of IgA could play a role in this respect. Carotenoids may further contribute to mucosal and gut barrier health, such as stabilizing tight junctions. This review highlights potential gut-related health-beneficial effects of carotenoids and emphasizes the current research gaps regarding carotenoid-GM interactions.

In Vitro-In Vivo Study of the Impact of Excipient Emulsions on the Bioavailability and Antioxidant Activity of Flavonoids: Influence of the Carrier Oil Type

The influence of the carrier oil type on the bioavailability and bioactivity of flavonoids (quercetin, kaempferol, and apigenin) was examined using in vitro digestion, in situ intestinal perfusion, and pharmacokinetic studies. Here, medium-chain triglycerides (MCTs), long-chain triglycerides (LCTs), or MCT/LCT mixtures (1:1, w/w) served as the oil phase of excipient emulsions. Overall, the bioavailability and antioxidant activity of flavonoids increased when they were coingested with excipient emulsions. The in vitro bioaccessibility of flavonoids was affected by the carrier oil: LCT (17.9-22.8%) > MCT/LCT (12.1-13.7%) > MCT (9.2-12.6%). These differences were mainly attributed to the fact that the mixed micelles formed after the digestion of LCTs had larger hydrophobic domains to solubilize more flavonoids. However, in vivo pharmacokinetic experiments showed that the flavonoid concentrations in rat serum were comparable for all carrier oils (p > 0.05). Our results assist in formulating excipient emulsions to enhance the efficacy of flavonoids.

Properties of curcumin-loaded zein-tea saponin nanoparticles prepared by antisolvent co-precipitation and precipitation

The properties of nutraceutical-loaded biopolymer nanoparticles fabricated by antisolvent co-precipitation (ASCP) and precipitation (ASP) were compared. Curcumin-loaded zein-tea saponin nanoparticles were fabricated using both methods and then their structural and physicochemical properties were characterized. The diameter of the nanoparticles prepared by ASCP were smaller (120-130 nm) than those prepared by ASP (140-160 nm). The encapsulation efficiency of the ASCP-nanoparticles (80.0%) was higher than the ASP-ones (71.0%) at a zein-to-curcumin mass ratio of 3:1, which was also higher than previous studies. The storage and light stability of curcumin was higher in zein-saponin nanoparticles than in zein nanoparticles. All nanoparticles had good water dispersibility after freeze-drying and rehydration. This study shows that nanoparticles produced by antisolvent co-precipitation have superior properties to those produced by antisolvent precipitation. The co-precipitation method leads to a higher encapsulation efficiency, smaller particle size, and greater storage stability, which may be advantageous for some applications.